WO2025134071 - MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS
National phase entry is expected:
Publication Number
WO/2025/134071
Publication Date
26.06.2025
International Application No.
PCT/IB2024/063068
International Filing Date
20.12.2024
Title **
[English]
MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS
[French]
LIPIDES IONISABLES À BASE D'ACIDE MALIQUE ET D'ACIDE GLUTARIQUE
Applicants **
SANOFI
Inventors
DENG, Hongfeng
KARVE, Shrirang
KAUSHAL, Neha
MA, Younan
MIKOCHIK, Peter Justin
NORTHEN, Trent
Priority Data
23307350.1
22.12.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5568 | |
| EPO | Filing, Examination, Granting | 21839 | |
| Japan | Filing, Examination, Granting | 2339 | |
| South Korea | Filing, Examination, Granting | 2442 | |
| USA | Filing, Examination, Granting | 8840 |
Total:
41,028
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are ionizable or cationic lipids of Formula (I): (I), or pharmaceutically acceptable salts thereof. The ionizable or cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.[French]
L'invention concerne des lipides ionisables ou cationiques de formule (I) : (I), ou des sels pharmaceutiquement acceptables de ceux-ci. Les lipides ionisables ou cationiques selon l'invention peuvent être utiles pour l'administration et l'expression d'ARNm et de protéine codée, par exemple, en tant que composant d'un véhicule d'administration liposomal, et peut par conséquent être utile pour traiter diverses maladies, troubles et états, tels que ceux associés à une déficience d'une ou de plusieurs protéines.